Developmental Cancer Therapeutics In the News
In the three decades since robots first entered the operating room, these increasingly sophisticated machines have helped surgeons perform more than a million procedures, all over the human body.
Now celebrating its 10th year, the Caltech and City of Hope Biomedical Research Initiative continues to change the future of science and medicine.
City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants.
The scientists developed a synthetic DNA molecule that disables tumor defense systems while inducing immune responses – a two-step immunotherapy that eliminated difficult-to-treat prostate cancer in experimental models
Linda Collins's outlook was bleak, thanks to her triple-negative breast cancer diagnosis, until City of Hope oncologist Yuan Yuan, M.D., Ph.D. helped develop a revolutionary new trial to help her.
This phase 2 trial studies the side effects and how well pembrolizumab and enobosarm work in treating patients with androgen receptor positive triple-negative breast cancer that has spread to other places in the body.
Patients with metastatic kidney cancer who have high rates of distress tend to have poorer overall survival compared to those with low distress, according to a new study by City of Hope researchers.
City of Hope's Linda Malkas, Ph.D., never envisioned a life in cancer research for herself. She wanted to be an astronaut, but after attending engineering school, she abandoned her interest in going into space.
City of Hope’s John Zaia, M.D., will lead the development of the phase 1 clinical trial for glioblastoma patients, which would genetically alter blood stem cells to better tolerate chemotherapy.
Advanced bladder cancer is particularly difficult to treat. The five-year survival rate for Stage 4 bladder cancer is only about 15 percent. Now, City of Hope researchers have discovered a that a novel drug blocks a key protein that drives the disease.
City of Hope researchers use novel technology to add new functionalities to already potent proteins.
Contemplating Cancer with a Poet and Patient
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research (AACR) in Chicago’s McCormick Place April 14 to 18.
Fourteen years ago, neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., began to travel to underserved countries to perform brain surgeries on disadvantaged children.
From Cuba to Calcutta, across Asia, throughout Europe and North and South America, City of Hope's Yuman Fong, M.D's go-anywhere philosophy has taken him everywhere. Some visits last only a few hours. But each carries a specific purpose.
Neurosurgeon and scientist Rahul Jandial says some symptoms should never be ignored by former cancer patients. More and more people are surviving cancer, thanks to advanced cancer treatments and screening tools.
Ravi Salgia, M.D., Ph.D., recently published in Scientific Reports about a novel and promising link between two NSCLC biomarkers. The study might help oncologists match patients with effective drug interventions against specific forms of NSCLC.
Julie F., 59, of Wisconsin, survived advanced small cell lung cancer after 29 rounds of chemotherapy, five weeks of radiation and experimental immunotherapy. This is her story.
Findings from a new study provide fresh insights into the treatment of women with metastatic breast cancer whose tumors are no longer responding to available treatments.